#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mitochondrial DNA depletion Progressive familial intrahepatic cholestasis Chondrosarcoma metastatic Cutaneous T-cell lymphoma stage II C3 glomerulopathy Antithrombin III deficiency Colon cancer Meningitis meningococcal Neurofibroma Haemophilia B without inhibitors Philadelphia positive acute lymphocytic leukaemia Malignant fibrous histiocytoma Colorectal cancer metastatic Primary mediastinal large B-cell lymphoma Hepatic cirrhosis More trials…

    Learn about Rare Diseases

    Chondrosarcoma – Life with Disease Leiomyosarcoma metastatic – Basic Information Congenital hypotransferrinaemia – Basic Information Small intestine leiomyosarcoma – Trials in Disease Haemophagocytic lymphohistiocytosis – Trials in Disease Mantle cell lymphoma stage IV – Basic Information Turner’s syndrome Factor IX deficiency Hereditary neuropathic amyloidosis – Treatment Adrenogenital syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ianalumab Bms-986458 Specific Nucleic Acid Sna-Veru HLX43 Levodopa Enasidenib Mesilate 177Lu-Rhpsma-10.1 Cl-Ad-Msc-002 Tigulixostat Oditrasertib Dc-806 Masitinib F125/10 Rineterkib Bbp-398 Crd-4730 ISPAGHULA HUSK Ag-946 Phosphate Captopril Ripretinib More therapies…

    Learn about Your Condition

    Urticaria cholinergic K-ras gene mutation Papulopustular rosacea Dyslipidaemia Cervix carcinoma stage IV Medication overuse headache Androgenetic alopecia Primary hypercholesterolaemia Ventricular tachycardia Mesothelioma Arterial tortuosity syndrome Hidradenitis Magnetic resonance imaging Urea cycle disorder Carcinoid tumour pulmonary More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Parc Tauli Hospital Universitari

Parc Tauli Hospital Universitari

Parc Del Tauli 1, Sabadell, 08208, Spain

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Long-Term Safety of Secukinumab for Patients with Polymyalgia Rheumatica

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Secukinumab
    Belgium Czechia Denmark France Germany Hungary +4

  • Study on Sotorasib for Patients with Unresectable Stage III Non-Small Cell Lung Cancer with KRAS Mutation

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage III
    Investigated Drugs:
    • Sotorasib
    Spain

  • Study on the Effects of DFV890 for Pain Relief in Patients with Knee Osteoarthritis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Osteoarthritis
    Investigated Drugs:
    • Codeine Phosphate Hemihydrate
    • Dfv890
    • Paracetamol
    Czechia Germany Hungary Romania Spain

  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Risankizumab
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Study of Eftilagimod Alpha and Paclitaxel in Patients with HER2-Negative/Low Metastatic Breast Cancer

    Not recruiting

    4 1 1
    Investigated Diseases:
    • Breast cancer stage IV
    Investigated Drugs:
    • Eftilagimod Alfa
    • Paclitaxel
    Belgium Spain

  • Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

    Not recruiting

    2 1
    Investigated Diseases:
    • Systemic scleroderma
    Investigated Drugs:
    • Fipaxalparant
    Austria France Germany Greece Italy Poland +3

  • Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Deutivacaftor
    • Tezacaftor
    • Vanzacaftor
    Austria Belgium Czechia Denmark France Germany +10

  • Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Atorvastatin
    • Rosuvastatin
    • Inclisiran
    Austria Belgium Bulgaria Croatia Czechia Denmark +18

  • Study of Pembrolizumab and Olaparib for Patients with Advanced Colorectal Cancer with DNA Repair Deficiency

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • Olaparib
    • Pembrolizumab
    Spain

  • Study on the Effectiveness and Safety of 7 vs. 14 Days of Antibiotic Treatment with Meropenem for Patients with Pseudomonas Aeruginosa Blood Infection

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Pseudomonas infection
    Investigated Drugs:
    • Amikacin
    • Avibactam
    • Aztreonam
    Spain
Previous Page
1 … 21 22 23 24 25 … 29
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!